SEC Company Response from ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895) (RCKT) — Aug 10, 2015
ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: Aug. 10, 2015 · CIK: 0001281895 · Accession: 0001193125-15-285140
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206027
Letter
UW Acceleration Request
VIA EDGAR
August 10, 2015
United States Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Attn: Christina DeRosa
Re: Inotek Pharmaceuticals Corporation (the “Company”)
Registration Statement on Form S-1 File No. 333-206027
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as representatives of the several underwriters of the Company’s proposed public offering of shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), we hereby join the Company’s request for acceleration of the effective date of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:00 p.m. (ET) on August 12, 2015, or as soon thereafter as practicable.
Pursuant to Rule 460 of the Act, we wish to advise you that we intend to distribute, either in printed or electronic form, approximately 850 copies of the Company’s preliminary prospectus relating to the Common Stock, dated August 10, 2015, to underwriters, dealers, institutions and others.
The undersigned, as representatives of the several underwriters, have complied and will continue to comply, and have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended.
[Signature page follows]
Very truly yours,
COWEN AND COMPANY, LLC
Show Raw Text
CORRESP
1
filename1.htm
UW Acceleration Request
VIA EDGAR
August 10, 2015
United States Securities and Exchange
Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Attn: Christina DeRosa
Re:
Inotek Pharmaceuticals Corporation (the “Company”)
Registration Statement on Form S-1 File No. 333-206027
Ladies and Gentlemen:
Pursuant to Rule 461
under the Securities Act of 1933, as amended (the “Act”), and as representatives of the several underwriters of the Company’s proposed public offering of shares of the Company’s common stock, par value $0.01 per
share (the “Common Stock”), we hereby join the Company’s request for acceleration of the effective date of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:00 p.m. (ET) on August
12, 2015, or as soon thereafter as practicable.
Pursuant to Rule 460 of the Act, we wish to advise you that we intend to distribute,
either in printed or electronic form, approximately 850 copies of the Company’s preliminary prospectus relating to the Common Stock, dated August 10, 2015, to underwriters, dealers, institutions and others.
The undersigned, as representatives of the several underwriters, have complied and will continue to comply, and have been informed by the
participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended.
[Signature page follows]
Very truly yours,
COWEN AND COMPANY, LLC
PIPER JAFFRAY & CO.
NOMURA SECURITIES INTERNATIONAL, INC.
Acting on their own behalf
and as representatives of several
underwriters
By: COWEN AND COMPANY, LLC
By:
/s/ Andy Mertz
Name: Andy Mertz
Title: Managing
Director
By: PIPER JAFFRAY & CO.
By:
/s/ Christie L. Christina
Name: Christie L. Christina
Title: Managing
Director
By: NOMURA SECURITIES INTERNATIONAL, INC.
By:
/s/ Rudy Balseiro
Name: Rudy Balseiro
Title: Managing
Director
[Signature Page to Acceleration Request]